Unlock instant, AI-driven research and patent intelligence for your innovation.

Estrogen receptor protein degraders

A technology of estrogen receptors and ligands, applied in the field of estrogen receptor protein degradation agents, can solve problems such as limiting therapeutic effects

Pending Publication Date: 2021-11-05
RGT UNIV OF MICHIGAN
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, although SNIPER ER degraders are effective in inducing partial degradation of ER proteins, they also induce autoubiquitination and proteasomal degradation of the E3 ligase (cIAP1 protein), which may limit their therapeutic efficacy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Estrogen receptor protein degraders
  • Estrogen receptor protein degraders
  • Estrogen receptor protein degraders

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0251] Compound Synthesis and Characterization

[0252] general chemical method.

[0253] Unless otherwise stated, all purchased reagents were used as received without further purification. 1 HNMR and 13 C NMR spectra were recorded on a Bruker Advance 400 MHz spectrometer. 1 H NMR spectra are reported in parts per million (ppm) downfield of tetramethylsilane (TMS). all 13C NMR spectra are all reported in ppm and passed 1 H is obtained by decoupling. In reporting spectral data, the format (δ) chemical shift (multiplicity, J value (Hz), integral) is used with the following abbreviations: s = singlet, d = doublet, t = triplet, q = quartet Peak, m = multiplet. MS analysis was performed using a Waters UPLC-mass spectrometer. The final compounds were all purified by C18 reverse phase preparative HPLC column using solvent A (0.1% TFA in H 2 O) and solvent B (0.1% TFA in MeCN) as eluents. All final compounds were >95% pure by UPLC-MS.

[0254] The synthesis of the final com...

Embodiment 2

[0377] biometrics

[0378] cell culture. Human breast cancer cell line MCF-7 ( HTB-22 TM ) and T47D ( HTB-133 TM ) was purchased from the American Type Culture Collection (ATCC) in Manassas, Virginia, and cultured in Dulbecco's Modified Eagle's medium (DMEM ) cultured and maintained. Cells with 3–8 passages after purchase were used in the experiments as described.

[0379] Western blot analysis. Western blot analysis was performed essentially as previously described (Hu et al., 2015, PMID: 26358219). Cells treated with the indicated compounds were subjected to radioimmunoprecipitation assay protein lysis and extraction buffer (25 mmol / L Tris.HCl, pH 7.6, 150 mmol / L NaCl, 1% Nonidet P-40, 1% sodium deoxycholate and 0.1% sodium lauryl sulfate). After determination of protein concentration by BCA assay (Fisher Scientific, Pittsburgh, PA), equal amounts of total protein were electrophoresed through a 10% SDS-polyacrylamide gel. Separated protein bands were transferred ...

Embodiment 3

[0385] Biological test results

[0386] Representative compounds of the disclosure were evaluated for their ability to induce ER degradation in the MCF-7 ER+ breast cancer cell line, fulvestrant was used as a control.

[0387] Western blot data for compounds 12-15 as figure 1 shown. Representative compounds of the disclosure ranging from 3 to 9 atoms in linker length were evaluated for their ability to induce ER degradation in MCF-7 cells at concentrations of 1 nM, 10 nM and 100 nM, including compound 15, fulvestrant (5) , RAD1901 (9) and Raloxifene (1) served as controls. Western blot data such as figure 2 shown. Compounds 15, 18, 19, 20 and 21 with linkers comprising 6-9 carbon atoms were surprisingly effective at inducing ER degradation at concentrations as low as 1 nM.

[0388] evaluated with different R 3 The ability of representative compounds of the present disclosure of the group to induce ER degradation in MCF-7 cells at concentrations of 1 nM, 10 nM and 100 nM...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present disclosure provides compounds represented by Formula (I): A-L-B and the salts or solvates thereof, wherein A, L, and B are as defined in the specification. Compounds having Formula I are estrogen receptor degraders useful for the treatment of cancer.

Description

technical field [0001] The present disclosure provides heterobifunctional small molecules as estrogen receptor (ER) protein degraders. ER degraders are useful in the treatment of various diseases, including breast cancer. Background technique [0002] Breast cancer (BC) is one of the most common malignancies in women worldwide. Breast cancer can be further subdivided into estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 (HER2)-positive (HER2+), and triple-negative subtypes based on tumor receptor status. 1 ER+ breast cancer occurs in approximately 80% of newly diagnosed breast cancer cases. 2 As members of the nuclear receptor family, the estrogen receptors ERα and ERβ are transcription factors that regulate gene expression and mediate the biological effects of estrogen. ERα and ERβ are widely expressed in different tissues, and ERα is considered to be the main mediator of estrogen signaling in the female reproductive tract and mammary gland. 3 ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D409/14C07D417/14A61P35/00A61K31/41A61K31/496
CPCC07D409/14C07D417/14A61P35/00A61K47/64A61K31/427A61K45/06A61K47/545A61K47/54A61K31/138A61K31/337A61K31/381A61K31/40A61K31/454A61K31/475A61K31/513A61K31/519A61K31/565A61K31/566A61K31/704A61K31/7068
Inventor 王绍梦胡建涛胡标王明亮徐福明苗不可言
Owner RGT UNIV OF MICHIGAN